-$0.14 Earnings Per Share Expected for Aptose Biosciences Inc (APTO) This Quarter

Equities research analysts predict that Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) will report earnings per share of ($0.14) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aptose Biosciences’ earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.15). Aptose Biosciences posted earnings per share of ($0.19) in the same quarter last year, which suggests a positive year over year growth rate of 26.3%. The company is expected to announce its next quarterly earnings report on Tuesday, March 27th.

According to Zacks, analysts expect that Aptose Biosciences will report full-year earnings of ($0.61) per share for the current fiscal year, with EPS estimates ranging from ($0.67) to ($0.54). For the next year, analysts expect that the company will report earnings of ($0.76) per share, with EPS estimates ranging from ($0.90) to ($0.61). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02.

APTO has been the subject of several recent analyst reports. Roth Capital restated a “buy” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research note on Monday, October 23rd. ValuEngine lowered Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, December 25th. HC Wainwright restated a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Aptose Biosciences in a research note on Wednesday, December 13th. Finally, Canaccord Genuity set a $7.00 price target on Aptose Biosciences and gave the company a “buy” rating in a research note on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $5.00.

A hedge fund recently raised its stake in Aptose Biosciences stock. Acadian Asset Management LLC lifted its holdings in Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,421 shares of the biotechnology company’s stock after purchasing an additional 33,766 shares during the period. Acadian Asset Management LLC owned about 0.17% of Aptose Biosciences worth $100,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.92% of the company’s stock.

Shares of Aptose Biosciences (NASDAQ:APTO) traded down $0.09 during mid-day trading on Thursday, hitting $2.93. The stock had a trading volume of 581,894 shares, compared to its average volume of 773,032. The firm has a market cap of $78.93, a PE ratio of -4.37 and a beta of 2.55. Aptose Biosciences has a fifty-two week low of $0.78 and a fifty-two week high of $3.90.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/01/0-14-earnings-per-share-expected-for-aptose-biosciences-inc-apto-this-quarter.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply